Biological activity of anomeric pairs of lipophilic glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine
- 40 Downloads
- 1 Citations
Abstract
We studied the capacity of anomeric pairs of α-and β-dodecyl, α-and β-(1-pentylhexyl), and α-and β-cyclododecyl glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine (muramyl dipeptide) to stimulate the nonspecific resistance of mice to intraperitoneal infection of Staphylococcus aureus and Escherichia coli cultures. Intraperitoneal pre-treatment with the test substances in a wide dose range increased survival of infected animals. No differences were found between the biological effects of α-and β-dodecyl and α-and β-(1-pentylhexyl) glycosides of muramyl dipeptide. An inverse relationship was found between stimulatory activity and dose of α-and β-cyclododecyl glycosides of muramyl dipeptide during sepsis caused by Staphylococcus aureus.
Key Words
muramyl dipeptide lipophilic α-and β-glycosides Staphylococcus aureus Escherichia coli resistancePreview
Unable to display preview. Download preview PDF.
References
- 1.A. E. Zemlyakov, V. N. Tsikalova, V. V. Tsikalov, et al., Bioorgan. Khim., 32, No. 4, 424–431 (2006).Google Scholar
- 2.A. E. Zemlyakov, V. V. Tsikalov, V. Ya. Chirva, et al., Ibid., 31, No. 6, 1–7 (2005).Google Scholar
- 3.O. V. Kalyuzhin, A. E. Zemlyakov, E. V. Kalyuzhina, et al., Byull. Eksp. Biol. Med., 134, No. 8, 186–190 (2002).Google Scholar
- 4.O. V. Kalyuzhin, N. G. Kalina, A. F. Bashtanenko, et al., Ibid., 135, No. 5, 531–535 (2003).CrossRefGoogle Scholar
- 5.O. V. Kalyuzhin, V. V. Kalyuzhin, A. E. Zemlyakov, et al., Ibid., 127, No. 5, 543–545 (1999).CrossRefGoogle Scholar
- 6.O. V. Kalyuzhin, M. V. Nelyubov, E. V. Kalyuzhina, et al., Ibid., 134, No. 9, 326–328 (2002).Google Scholar
- 7.O. V. Kalyuzhin, B. B. Fuchs, N. V. Bovin, et al., Ibid., 117, No. 5, 510–513 (1994).CrossRefGoogle Scholar
- 8.R. M. Khaitov, I. S. Gushchin, B. F. Pinegin, and A. I. Zebrev, Manual on Experimental (Preclinical) Study of New Pharmacological Substances [in Russian], Moscow (2000), pp. 257–263.Google Scholar
- 9.W. E. Fogler and I. J. Fidler, Int. J. Immunopharmacol., 9, No. 2, 141–150 (1987).CrossRefPubMedGoogle Scholar
- 10.O. V. Kalyuzhin, A. E. Zemlyakov, and B. B. Fuchs, Ibid., 18, No. 11, 651–659 (1996).CrossRefPubMedGoogle Scholar